SureTrader
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 1/21/2018 7:25:54 AM - Followers: 745 - Board type: Free - Posts Today: 4

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Amended Statement of Ownership (sc 13g/a) 01/11/2018 04:35:53 PM
IPIX News: Statement of Changes in Beneficial Ownership (4) 12/27/2017 03:08:40 PM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
PostSubject
#211306  Sticky Note Chill Off! Data looks good! PlentyParanoid 01/03/18 12:19:54 PM
#211222  Sticky Note Bottom Line noretreat 01/03/18 07:43:11 AM
#211057  Sticky Note IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patent sox040713 01/01/18 09:21:12 PM
#210140  Sticky Note A must read to due diligence for any tryz 12/27/17 10:48:29 AM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#213600   Agree....Can’t quit laughing ! WILD_4_IPIX 01/21/18 07:25:54 AM
#213599   Amen 58 ! West Palm Rocks ! Heading WILD_4_IPIX 01/21/18 07:01:04 AM
#213598   Your logic is good but there are some Amatuer17 01/21/18 07:00:12 AM
#213597   farrell good post.. cybermich 01/21/18 01:02:13 AM
#213596   At what price would I cash in? Depends farrell90 01/20/18 11:36:36 PM
#213595   As of now 33.00 plus is where I DevilDogg84 01/20/18 11:28:59 PM
#213594   Do me a favor. Take the time and DaubersUP 01/20/18 09:40:42 PM
#213593   Prurisol Orally-delivered psoriasis drug candidate has successfully georgejjl 01/20/18 09:08:23 PM
#213592   BP's interests in the Big Three sox040713 01/20/18 08:50:23 PM
#213591   Now your talkin! Jhawker 01/20/18 08:42:04 PM
#213589   The Innovation Pharmaceutical's Prurisol Phase 2b trial has georgejjl 01/20/18 07:54:19 PM
#213588   SS.....that was the funniest post of the week....thanks falcon74 01/20/18 06:48:13 PM
#213587   The drugs are more valuable today than they septmike09 01/20/18 06:29:27 PM
#213586   I'm in for New York as well as cabel 01/20/18 06:25:13 PM
#213585   Paulie I'd rather meet in West Palm, you 58nout 01/20/18 06:12:57 PM
#213584   What's expected here? What do we expect to hear? georgejjl 01/20/18 06:11:20 PM
#213583   Good points to reinforce. farrell90 01/20/18 05:03:42 PM
#213582   If Leo can pull 100 million upfront for septmike09 01/20/18 03:15:55 PM
#213581   My belief is that the vast majority will petemantx 01/20/18 02:43:53 PM
#213580   IMO or IMHO is not needed on each AKBrakeman 01/20/18 02:37:04 PM
#213579   Great post from PP on valuation for B-OM DaubersUP 01/20/18 02:17:38 PM
#213578   50 even snayeman 01/20/18 01:25:59 PM
#213577   LONG and STRONG for THREE years. Ten scottsmith 01/20/18 01:23:43 PM
#213576   I've been here for almost 5.5 years and JPsooner 01/20/18 01:10:48 PM
#213575   Let’s see what P phase 2b shows. That DaubersUP 01/20/18 01:01:39 PM
#213574   That is not the attitude to have. IMO. DaubersUP 01/20/18 01:00:35 PM
#213573   For me it's an investment, so I will frrol 01/20/18 12:39:39 PM
#213572   It depends what progress/news starts to drive the LilyGDog 01/20/18 12:16:57 PM
#213571   Question for the true LONGS who have been Here Today 01/20/18 11:18:29 AM
#213570   Few years back reunion was supposed to happen jav0033 01/20/18 11:14:45 AM
#213569   That's a deal. I'll bring 58 and Focusakker 01/20/18 11:01:11 AM
#213568   Yes. Management could make a deal tomorrow for frrol 01/20/18 10:55:34 AM
#213566   Rdunn, are you discounting Adam Feuerstein? I think PlentyParanoid 01/20/18 09:17:07 AM
#213565   I agree a CEO's responsibility is to manage Here Today 01/20/18 07:56:08 AM
#213564   it is absolutely his job to manage shareholder MXAMDUD 01/20/18 07:49:57 AM
#213562   61 Second Avenue? Sounds good. Here Today 01/20/18 07:36:00 AM
#213560   Start at Dempsey's and I will buy the farrell90 01/19/18 11:47:42 PM
#213559   It is from Citrati, post 213051... last sentence farrell90 01/19/18 11:28:55 PM
#213557   It will have to be mid May. That’s Cassius Longinus 01/19/18 10:41:55 PM
#213556   Yes. They have an opportunity to make Multi-billions Williamsc 01/19/18 10:41:02 PM
#213555   I will be there! JUST 10-11-12 01/19/18 10:02:59 PM
#213553   William C If a big pharma likes what they Echo20 01/19/18 09:21:20 PM
#213552   William C Would $1.2 billion and 12 percent be Too Echo20 01/19/18 09:17:00 PM
#213551   New investors, the statement "25% of today's volume sox040713 01/19/18 09:11:29 PM
#213550   To all the True believers in management, the Here Today 01/19/18 09:07:32 PM
#213547   No it won't. P has nothing to do septmike09 01/19/18 08:58:21 PM
#213546   Leo shifted strategy away from B-Absssi phase 3 Rdunn88 01/19/18 08:54:30 PM
#213542   FINRA short sales of IPIX AlanC 01/19/18 08:01:54 PM
#213540   I'd be afraid if I was out this Williamsc 01/19/18 07:44:20 PM
#213539   It's funny how many people want to knock septmike09 01/19/18 07:31:40 PM
PostSubject